Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Brainstorm Cell Therapeutics Inc | BCLI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.532 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.532 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.134 - 3.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.532 | USD |
Brainstorm Cell Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 48.98M | - | 0 | -17.19M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Brainstorm Cell Therapeu... News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCLI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.50 | 0.61 | 0.4523 | 0.5341936 | 403,309 | 0.032 | 6.40% |
| 1 Month | 0.6085 | 0.75 | 0.45 | 0.6173811 | 1,013,068 | -0.0765 | -12.57% |
| 3 Months | 0.385 | 0.792699 | 0.27 | 0.5058617 | 992,963 | 0.147 | 38.18% |
| 6 Months | 0.1534 | 0.792699 | 0.134 | 0.3217586 | 1,804,960 | 0.3786 | 246.81% |
| 1 Year | 2.79 | 3.34 | 0.134 | 0.414584 | 1,403,646 | -2.26 | -80.93% |
| 3 Years | 3.53 | 4.70 | 0.134 | 1.12 | 629,967 | -3.00 | -84.93% |
| 5 Years | 4.05 | 17.95 | 0.134 | 3.43 | 617,655 | -3.52 | -86.86% |
Brainstorm Cell Therapeu... Description
| Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases. |
